Stay updated on Trastuzumab Deruxtecan in HER2 Mutant NSCLC Clinical Trial
Sign up to get notified when there's something new on the Trastuzumab Deruxtecan in HER2 Mutant NSCLC Clinical Trial page.

Latest updates to the Trastuzumab Deruxtecan in HER2 Mutant NSCLC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check17 days agoChange DetectedThe footer now identifies the site revision as v3.8.0 instead of v3.7.2.SummaryDifference0.1%

- Check24 days agoChange DetectedA site-wide NIH notice announces updates and FAQs about federal agencies’ transition from using “Artificial Intelligence” to “Super Intelligence.”SummaryDifference0.6%

- Check31 days agoChange DetectedThe footer’s ClinicalTrials.gov revision label was updated from v3.7.1 to v3.7.2.SummaryDifference0.1%

- Check39 days agoChange DetectedThe footer revision identifier was updated from v3.7.0 to v3.7.1.SummaryDifference0.1%

- Check59 days agoChange DetectedThe study record history now shows the latest revision (v3.7.0) for the page, indicating an update to the record. The older revision (v3.6.6) has been removed from the visible history.SummaryDifference0.1%

- Check80 days agoChange DetectedThe study record history shows the site revision updated to v3.6.6 (replacing v3.6.5). This reflects a software release rather than any modification to the trial data or records.SummaryDifference0.1%

Stay in the know with updates to Trastuzumab Deruxtecan in HER2 Mutant NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Trastuzumab Deruxtecan in HER2 Mutant NSCLC Clinical Trial page.